Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Quentis Therapeutics

Quentis Therapeutics
PRIVATE STATUS
Accelerator/Inc LATEST DEAL TYPE
9 INVESTORS
Description

Developer of immuno-therapeutics designed to address ER stress in multiple diseases. The company inhibitor is designed to target ER stress pathways and awaken the immune system's ability to fight cancer, enabling patients to get access to new treatments for cancer.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 430 East 29th Street
  • Suite 1005
  • New York, NY 10016
  • United States

+1 (646) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Quentis Therapeutics’s full profile, request a free trial.

Quentis Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Accelerator/Incubator 01-Sep-2018 000.00 Completed Product Development
3. Early Stage VC (Series A) 27-Feb-2018 000.00 000.00 000.00 Completed Product Development
2. Seed Round 22-Nov-2017 $2M $5M 0000 Completed Startup
1. Seed Round 09-Jun-2016 $3M $3M 000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Quentis Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
To view this company’s complete Cap Table, request access »

Quentis Therapeutics Competitors (39)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Corvidia Venture Capital-Backed Waltham, MA 0 000.00 00000000000 000.00
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
00000000 Venture Capital-Backed Tübingen, Germany 000 00000 00000000000 00000
00000000000 Angel-Backed Culver City, CA 00000 000000000000 00000
00000000 Formerly VC-backed Munich, Germany 000.00 000000&0 000.00
To view this company’s complete list of competitors, request access »

Quentis Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
JLABS Accelerator/Incubator Minority 000 0000 000000 0
AbbVie Ventures Corporate Venture Capital Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
New York Ventures Venture Capital Minority 000 0000 000000 0
Polaris Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Quentis Therapeutics Executive Team (5)

Name Title Board
Seat
Contact
Info
Michael Aberman MD Chief Executive Officer, President & Board Member
Jeanne Magram Ph.D Chief Scientific Officer
Sarah Bettigole Ph.D Director of Biology & Scientific Co-Founder
Juan Cubillos-Ruiz Ph.D Scientific Co-Founder & Advisor
Joseph Vacca Ph.D Head of Chemistry

Quentis Therapeutics Board Members (7)

Name Representing Role Since Contact
Info
Amy Schulman JD Polaris Partners Board Member 000 0000
Carlo Rizzuto Ph.D Versant Venture Management Board Member 000 0000
Charles Kunsch Ph.D AbbVie Ventures Board Observer 000 0000
Laurie Glimcher MD Self Scientific Co-Founder & Chairman, Scientific Advisory Board 000 0000
Mark Murcko Ph.D Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »